Oragenics Inc (OGEN)
:OGEN
Want to see OGEN full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/A
Date:―
No summary available
Positive Factors
Leadership Change
The appointment of Janet Huffman as CEO and CFO may bring strategic leadership and operational improvements, potentially enhancing the company's focus on financial restructuring and growth.
Negative Factors
Financial Distress
Ongoing financial distress, characterized by persistent losses and negative equity, threatens long-term viability and limits the company's ability to invest in growth opportunities.
Read all positive and negative factors
Positive Factors
Negative Factors
Leadership Change
The appointment of Janet Huffman as CEO and CFO may bring strategic leadership and operational improvements, potentially enhancing the company's focus on financial restructuring and growth.
Read all positive factors
Oragenics (OGEN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.64M
Dividend YieldN/A
Average Volume (3M)211.78K
Price to Earnings (P/E)―
Beta (1Y)2.07
Revenue GrowthN/A
EPS Growth84.00%
CountryUS
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,511,957
10 Day Avg. Volume326,842
30 Day Avg. Volume211,777
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-1.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.54
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Oragenics Business Overview & Revenue Model
Company Description
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respir...
How the Company Makes Money
Oragenics generates revenue primarily through research and development collaborations, grants, and potential milestone payments from strategic partnerships. The company focuses on advancing its product candidates through various stages of clinical...
Oragenics Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -6.31M | -9.36M | -10.54M | -20.60M | -14.23M | -15.65M |
| Net Income | -9.83M | -9.84M | -10.57M | -20.66M | -14.29M | -15.71M |
Balance Sheet | ||||||
| Total Assets | 7.49M | 10.07M | 1.47M | 4.97M | 14.76M | 28.23M |
| Cash, Cash Equivalents and Short-Term Investments | 6.11M | 8.40M | 864.84K | 3.48M | 11.43M | 27.27M |
| Total Debt | 56.13K | 227.35K | 328.53K | 322.51K | 624.53K | 797.21K |
| Total Liabilities | 1.31M | 1.79M | 1.68M | 1.80M | 1.75M | 1.74M |
| Stockholders Equity | 6.18M | 8.28M | -211.88K | 3.17M | 13.01M | 26.49M |
Cash Flow | ||||||
| Free Cash Flow | -9.33M | -9.25B | -8.60M | -8.29M | -15.36M | -13.51M |
| Operating Cash Flow | -9.33M | -9.25B | -8.60M | -7.29M | -15.23M | -13.47M |
| Investing Cash Flow | 4.00M | 0.00 | 0.00 | -936.28K | -115.52K | -43.88K |
| Financing Cash Flow | 12.02M | 16.78B | 5.98M | 283.88K | -494.92K | 23.14M |
Oragenics Technical Analysis
Negative
0.72
Price Trends
0.65
Negative
0.73
Negative
0.93
Negative
Market Momentum
-0.02
Positive
43.68
Neutral
24.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OGEN, the sentiment is Negative. The current price of 0.72 is above the 20-day moving average (MA) of 0.60, above the 50-day MA of 0.65, and below the 200-day MA of 0.93, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 43.68 is Neutral, neither overbought nor oversold. The STOCH value of 24.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OGEN.
Oragenics Risk Analysis
Oragenics disclosed 69 risk factors in its most recent earnings report. Oragenics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oragenics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $2.64M | -0.27 | -168.95% | ― | ― | 84.00% | |
50 Neutral | $5.34M | -0.22 | -82.17% | ― | -34.06% | 79.61% | |
46 Neutral | $3.90M | ― | -199.52% | ― | ― | 97.37% | |
| ― | $1.26M | -0.06 | -263.57% | ― | -61.81% | 99.68% |
* Healthcare Sector Average
OGEN
Oragenics
0.58
-5.18
-89.86%
INM
InMed Pharmaceuticals
1.61
-1.09
-40.37%
GRI
GRI Bio
2.20
-36.44
-94.31%
KTTA
Pasithea Therapeutics Corp
0.72
-0.21
-22.37%
ONCO
Onconetix
0.11
-35.16
-99.69%
Oragenics Corporate Events
Executive/Board Changes
Oragenics Adjusts Executive Compensation Plan
Neutral
Dec 15, 2025
On December 11, 2025, Oragenics, Inc. announced adjustments to its executive compensation plan. The Board of Directors approved a 5% salary increase for CEO Janet Huffman, effective January 1, 2026, raising her annual base salary to $341,250. Addi...
Delistings and Listing ChangesLegal ProceedingsPrivate Placements and FinancingRegulatory Filings and Compliance
Oragenics Regains NYSE Compliance After Public Offering
Positive
Oct 21, 2025
On October 16, 2025, Oragenics settled a dispute with Ladenburg Thalmann Co., Inc., agreeing to pay $700,000 to resolve claims related to an investment banking agreement from December 2022. This settlement followed a confidential arbitration init...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―